Selective C-reactive protein apheresis in ST-elevation myocardial infarction: Design and rationale of the randomized CRP-STEMI trial
Study context
- Population
- ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) within 12 hours of symptom onsetplanned enrolment
- Participants
- 202 patients
- Planned comparison
- Selective C-reactive protein (CRP) apheresis using the PentraSorb-CRP system, in addition to standard care, vs standard care
- Primary endpoint
- infarct size as assessed by late gadolinium enhanced cardiac magnetic resonance
- Follow-up
- 5 ± 2 days after PCI
Methodological detailsdesign and rationale paper, 5 tertiary care centers in Austria and Germany
- Design and rationale paper
- 5 tertiary care centers in Austria and Germany
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Selective C-reactive protein apheresis in ST-elevation myocardial infarction: Design and rationale of the randomized CRP-STEMI trial. Am Heart J. Published 28 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →